A Phase II Study of Sequential Dose-Dense Chemotherapy and Dose-Intense Erlotinib for the Initial Treatment of Advanced Non-Small Cell Lung Cancer.

Trial Profile

A Phase II Study of Sequential Dose-Dense Chemotherapy and Dose-Intense Erlotinib for the Initial Treatment of Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Docetaxel; Pegfilgrastim
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Jul 2013 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record (NCT00723138).
    • 09 Jul 2013 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record (NCT00723138).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top